Should I Buy IONS? IONS 2026 Analysis

Should You Buy Ionis Pharmaceuticals Inc (IONS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

83.390

1 Day change

1.79%

52 Week Range

86.150

Analysis Updated At

2026/01/26

Ionis Pharmaceuticals Inc (IONS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong positive catalysts, including recent European Commission approval for Dawnzera, significant analyst optimism with raised price targets, and hedge fund buying activity. Despite some short-term technical weakness and insider selling, the long-term growth potential and multiple upcoming catalysts make this stock a compelling choice for a patient investor.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 54.566, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 78.906, with resistance at 82.356 and support at 75.457.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

European Commission approval for Dawnzera, which enhances Ionis' financial position with a $15 million milestone payment and tiered royalties.
Hedge fund buying activity increased by 242.57% last quarter.
Analysts have consistently raised price targets, with most ratings being Overweight or Buy.
Upcoming Phase 3 readouts and the potential for significant revenue growth from Tryngolza and other products.

Neutral/Negative Catalysts

Insiders have increased selling activity by 578.95% in the last month.
Financial performance shows a decline in net income (-8.45% YoY) and EPS (-15.79% YoY), though revenue has grown.
Short-term technical indicators suggest bearish momentum.

Financial Performance

In Q3 2025, revenue increased by 17.12% YoY to $156.7M, driven by strong Tryngolza sales. However, net income dropped by 8.45% YoY to -$128.6M, and EPS declined by 15.79% YoY to -0.8. Gross margin remains high at 98.51%, though it slightly decreased by 0.70% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly optimistic about Ionis Pharmaceuticals, with multiple firms raising price targets significantly (e.g., Wells Fargo to $100, RBC Capital to $95, and H.C. Wainwright to $110). The consensus is positive, with expectations of value creation from upcoming catalysts and strong commercial execution.

14 Analyst Rating

Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 92.67 USD with a low forecast of 65 USD and a high forecast of 110 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

1 Hold

0 Sell

Strong Buy

Current: 81.920

Low

Averages

92.67

High

110

Current: 81.920

Low

Averages

92.67

High

110

Barclays

Overweight

initiated

$95

AI Analysis

2026-01-27

New

Reason

Barclays

Price Target

$95

AI Analysis

2026-01-27

New

initiated

Overweight

Reason

Barclays assumed coverage of Ionis Pharmaceuticals with an Overweight rating and $95 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Wells Fargo

NULL

Overweight

upgrade

$82 -> $100

2026-01-05

Reason

Wells Fargo

Price Target

$82 -> $100

2026-01-05

upgrade

NULL

Overweight

Reason

Wells Fargo raised the firm's price target on Ionis Pharmaceuticals to $100 from $82 and keeps an Overweight rating on the shares. Following a strong 2025, the firm sees further value creation on multiple catalysts in 2026, including Phase 3 readouts for bepirovirsen in cHBV, pelacarsen in Lp(a) and WAINUA in ATTR-CM.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IONS

Unlock Now

IONS Should I Buy

IONS Should I Buy

Should You Buy Ionis Pharmaceuticals Inc (IONS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch